Sumitomo Pharma Co Stock Net Income
| SMDPY Stock | 14.75 0.00 0.00% |
As of the 17th of February 2026, Sumitomo Pharma has the Coefficient Of Variation of 812.4, risk adjusted performance of 0.1071, and Variance of 12.59. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sumitomo Pharma, as well as the relationship between them.
Sumitomo Pharma's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sumitomo Pharma's valuation are provided below:Sumitomo Pharma Co does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Sumitomo |
Sumitomo Pharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sumitomo Pharma's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sumitomo Pharma.
| 11/19/2025 |
| 02/17/2026 |
If you would invest 0.00 in Sumitomo Pharma on November 19, 2025 and sell it all today you would earn a total of 0.00 from holding Sumitomo Pharma Co or generate 0.0% return on investment in Sumitomo Pharma over 90 days. Sumitomo Pharma is related to or competes with Livzon Pharmaceutical, Siegfried Holding, United Laboratories, H Lundbeck, Carl Zeiss, Hikma Pharmaceuticals, and Shenzhen Hepalink. More
Sumitomo Pharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sumitomo Pharma's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sumitomo Pharma Co upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1034 | |||
| Maximum Drawdown | 28.82 |
Sumitomo Pharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sumitomo Pharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sumitomo Pharma's standard deviation. In reality, there are many statistical measures that can use Sumitomo Pharma historical prices to predict the future Sumitomo Pharma's volatility.| Risk Adjusted Performance | 0.1071 | |||
| Jensen Alpha | 0.408 | |||
| Total Risk Alpha | 0.1632 | |||
| Treynor Ratio | 1.37 |
Sumitomo Pharma February 17, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1071 | |||
| Market Risk Adjusted Performance | 1.38 | |||
| Mean Deviation | 0.8601 | |||
| Coefficient Of Variation | 812.4 | |||
| Standard Deviation | 3.55 | |||
| Variance | 12.59 | |||
| Information Ratio | 0.1034 | |||
| Jensen Alpha | 0.408 | |||
| Total Risk Alpha | 0.1632 | |||
| Treynor Ratio | 1.37 | |||
| Maximum Drawdown | 28.82 | |||
| Skewness | 8.12 | |||
| Kurtosis | 66.0 |
Sumitomo Pharma Backtested Returns
Sumitomo Pharma appears to be not too volatile, given 3 months investment horizon. Sumitomo Pharma owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.13, which indicates the firm had a 0.13 % return per unit of risk over the last 3 months. We have found sixteen technical indicators for Sumitomo Pharma Co, which you can use to evaluate the volatility of the company. Please review Sumitomo Pharma's Variance of 12.59, risk adjusted performance of 0.1071, and Coefficient Of Variation of 812.4 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Sumitomo Pharma holds a performance score of 10. The entity has a beta of 0.31, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Sumitomo Pharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sumitomo Pharma is expected to be smaller as well. Please check Sumitomo Pharma's information ratio and day median price , to make a quick decision on whether Sumitomo Pharma's existing price patterns will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Sumitomo Pharma Co has no correlation between past and present. Overlapping area represents the amount of predictability between Sumitomo Pharma time series from 19th of November 2025 to 3rd of January 2026 and 3rd of January 2026 to 17th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sumitomo Pharma price movement. The serial correlation of 0.0 indicates that just 0.0% of current Sumitomo Pharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 2.24 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Sumitomo Pharma Co reported net income of 56.41 B. This is much higher than that of the sector and significantly higher than that of the Net Income industry. The net income for all United States stocks is notably lower than that of the firm.
Sumitomo Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sumitomo Pharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sumitomo Pharma could also be used in its relative valuation, which is a method of valuing Sumitomo Pharma by comparing valuation metrics of similar companies.Sumitomo Pharma is currently under evaluation in net income category among its peers.
Sumitomo Fundamentals
| Return On Equity | -0.0068 | |||
| Return On Asset | 0.0178 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 2.85 B | |||
| Shares Outstanding | 397.29 M | |||
| Shares Owned By Institutions | 0.10 % | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 560.03 B | |||
| Gross Profit | 402.91 B | |||
| EBITDA | 124.36 B | |||
| Net Income | 56.41 B | |||
| Total Debt | 243.96 B | |||
| Book Value Per Share | 1,626 X | |||
| Cash Flow From Operations | 31.24 B | |||
| Earnings Per Share | 0.24 X | |||
| Number Of Employees | 6.99 K | |||
| Beta | 0.36 | |||
| Market Capitalization | 3.05 B | |||
| Total Asset | 1.31 T | |||
| Net Asset | 1.31 T | |||
| Last Dividend Paid | 28.0 |
About Sumitomo Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sumitomo Pharma Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sumitomo Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sumitomo Pharma Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Sumitomo Pink Sheet Analysis
When running Sumitomo Pharma's price analysis, check to measure Sumitomo Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sumitomo Pharma is operating at the current time. Most of Sumitomo Pharma's value examination focuses on studying past and present price action to predict the probability of Sumitomo Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sumitomo Pharma's price. Additionally, you may evaluate how the addition of Sumitomo Pharma to your portfolios can decrease your overall portfolio volatility.